ReviewCNS drugs2018
The Cholinergic System as a Treatment Target for Opioid Use Disorder.
Review in CNS drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Efficacy of bupivacaine liposome transversus abdominis plane block in enhancing postoperative recovery following laparoscopic colorectal cancer resection.Langenbeck's archives of surgery · 2025Trial
- Double-Blind Placebo-Controlled Trial of Galantamine for Methadone-Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use.The American journal on addictions · 2019Trial
- Feasibility and effects of galantamine on cognition in humans with cannabis use disorder.Pharmacology, biochemistry, and behavior · 2019Trial
- Article
- Case Report: Delirium and complications resulting from the abuse of compound liquorice tablets.Frontiers in psychiatry · 2026Article
- Withdrawal-Induced Delirium in Opioid Dependence: A Systematic Review.Brain sciences · 2025Review
- Competitive Antagonism of Xylazine on α7 Nicotinic Acetylcholine Receptors and Reversal by Curcuminoids.ACS chemical neuroscience · 2025Article
- Cholinergic regulation of decision making under risk of punishment.Neurobiology of learning and memory · 2025Article
- M3 Receptor Pathway Stimulates Rapid Transcription of the CB1 Receptor Activation through Calcium Signalling and the CNR1 Gene Promoter.International journal of molecular sciences · 2023Article
- CpH methylome analysis in human cortical neurons identifies novel gene pathways and drug targets for opioid use disorder.Frontiers in psychiatry · 2022Article
- Recent Advances in the Treatment of Opioid Use Disorder.Current pain and headache reports · 2021Review
- Cholestasis and behavioral disorders.Gastroenterology and hepatology from bed to bench · 2021Review
- Review
- Acetylcholine Muscarinic Receptors in Ventral Hippocampus Modulate Stress-Induced Anxiety-Like Behaviors in Mice.Frontiers in molecular neuroscience · 2020Article
- Letter to the Editor: A Novel Therapeutic for Opioid Use Disorder Targeting the Cholinergic System.The American journal on addictions · 2019Article
- Comparative biophysical characterization: A screening tool for acetylcholinesterase inhibitors.PloS one · 2019Article
- Mechanisms and Clinical Features of Co-occurring Opioid and Nicotine Use.Current addiction reports · 2019Article
- Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence.International review of psychiatry (Abingdon, England)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Opioid overdoses recently became the leading cause of accidental death in the US, marking an increase in the severity of the opioid use disorder (OUD) epidemic that is impacting global health. Current treatment protocols for OUD are limited to opioid medications, including methadone, buprenorphine, and naltrexone. While these medications are effective in many cases, new treatments are required to more effectively address the rising societal and interpersonal costs associated with OUD. In this article, we review the opioid and cholinergic systems, and examine the potential of acetylcholine (ACh) as a treatment target for OUD. The cholinergic system includes enzymes that synthesize and degrade ACh and receptors that mediate the effects of ACh. ACh is involved in many central nervous system functions that are critical to the development and maintenance of OUD, such as reward and cognition. Medications that target the cholinergic system have been approved for the treatment of Alzheimer's disease, tobacco use disorder, and nausea. Clinical and preclinical studies suggest that medications such as cholinesterase inhibitors and scopolamine, which target components of the cholinergic system, show promise for the treatment of OUD and further investigations are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.